Epithelial and breast cancer-related genes failed to predict response to therapy and disease progression when assessed in EpCAM-based enriched CTCs in patients with metastatic breast cancer starting first-line cisplatin-based therapy or treated with anthracycline and taxane [135,159,165]. Here, EPCAM is linked to breast carcinoma.